Agreements are signed on Grippol Plus flu vaccine manufacturinglocalization in the Republic of Belarus and Iran.
Imoferaza®, an innovative special care cosmetic cream for post-trauma, post-surgical and post-acne scars is launched to the market.
The WHO approves bovhyaluronidase azoximer as the INN for Longidaze®.
The Russian Ministry of Health licenses Petrovax Pharm to manufacture Grippol® Plus, a Russian influenza vaccine, using flu antigens produced by St. Petersburg Research Institute for Vaccines and Sera of Russia’s Federal Medical and Biological Agency.
Partnership with Boehringer Ingelheim to localize a full-cycle manufacturing of the most advanced cardiovascular pharmaceutical products. The first commercial Metalyse® batches are produced.
Polyoxidonium® is a two-time winner of the Russian Pharma Awards (2016 and 2017). Polyoxidonium® tablets label is extended to include children aged 3+ years. A Post-Authorization Safety Study (PASS) for Polyoxidonium® is successfully completed in Europe (Slovakia).
Petrovax Pharm is announced the winner of the All-Russia Contest «Russian Business Leaders: Performance and Commitment’2017» in the category «For the Dynamic Development of Business».
Grippol® Quadrivalent registration dossier is submitted for review and approval.